
Please try another search
Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. The company is developing Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas; and SP-2-225, a pre-clinical class IIb product candidate that effects on the regulation of the immune system. It is also developing SP-1-303, a pre-clinical selective Class I HDAC for use in the treatment of ER positive breast cancers; and SP-1-161, a HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway. The company was founded in 2012 and is headquartered in Gaithersburg, Maryland.
Name | Age | Since | Title |
---|---|---|---|
J. Martin Brown | - | 2017 | Member of Scientific Advisory Committee |
Alejandro Villagra | - | 2017 | Member of Scientific Advisory Committee |
Ralph R. Weichselbaum | - | 2013 | Member of Scientific Advisory Committee |
Joseph Armstrong | - | 2021 | Member of Scientific Advisory Committee |
Joseph Tung | 41 | 2025 | Independent Director |
Oleh Nabyt | 31 | 2025 | Independent Director |
Theodore L. Phillips | 92 | 2013 | Chairman of Scientific Advisory Committee |
Steven Richards | 56 | 2012 | Independent Director |
George Scorsis | 48 | 2025 | Independent Chairman of the Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review